LucidQuest’s Post

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #biotech #healthcare

At the BIO Investor Forum in SF today. Looking forward to connect with investors and strategic Pharma partners as we gear up to deliver on the next value inflections in our drug discovery journey

💡 Gratitude to our esteemed panel members at the 19th BioPharma Drug Discovery Nexus! Their insights and expertise are shaping the future of drug discovery. Your invaluable insights and expertise have ignited engaging discussions and fueled innovation in the field of drug discovery. #DrugDiscovery #Paneldiscussion #baselevent #BioPharmaNexus #NexusConference #Discoverytools

Thoughts on this? >> Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #biotech #healthcare

Thoughts on this? >> Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #productmarketing

We are proud to share that we have helped a top 10 CMO secure 25 new business meetings with pharma and biotech leaders while travelling this week. Since 2013, we have helped our clients connect with the right decision-makers in the #pharma, #biotech, and #medtech industries. We look forward to continuing our mission of connecting people intelligently in the pharma and biotech service providers. 👉 𝗜𝗳 𝘆𝗼𝘂'𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗺𝗼𝗿𝗲 𝘀𝗲𝗻𝗱 𝘂𝘀 𝗮 𝗺𝗲𝘀𝘀𝗮𝗴𝗲 𝗼𝗻 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻. 👏Celebrating 10 years of connecting people in the pharma and biotech industry! #PharmaTargeting - The home of Pharma Service Providers. #pharmaserviceproviders Anil Kumar

New: Former Novartis CEO Joe Jimenez and the pharma's long-time research leader Mark Fishman are targeting $400 million for their third fund at Aditum Bio. The Oakland, CA-based firm in-licenses drugs, sets up a company around them and takes the experimental medicines through clinical development toward an M&A exit, like it has done with Versanis Bio, bought by Eli Lilly for up to $1.9 billion last year. Aditum has created 10 companies so far. “I was very clear with all of my investors that out of the 10 companies, I expect only three of them to provide good data, and seven of them will shut down,” Jimenez said in an interview with Endpoints News last fall. “Many times in pharma, if you’re in Phase 2 and you don’t get a positive readout, there’s a project team that’s willing to convince management that all they have to do is change the patient population, and they’re going to have success. That’s not what we’re about.” #biotech #vc #lifesciences #venturecapital #drugdevelopment

"(...) Medicine Development and commercialization will be dominated by Data companies with Biotech and Pharma companies playing the role of a substrate supplier to algorithms" (Dr. Michael Zaiac) The writing is on the wall. If this happens, it will be a seismic shift affecting all aspects of healthcare. For many established players, this will pose a major threat to their business model. But within this threat, there is also opportunity. For patients, for Data companies - and for a few Pharma companies who get it right. Thanks Michael Zaiac for spelling it out and Bora Erdemli for posting! #futureofhealthcare #datadrivenmedicine #genAI

Results speak louder than words 😊

A massive thank you to Kevin Harris for delivering an inspirational talk to our team a few weeks ago! With over 25 years of experience, Kevin has a remarkable track record in launching and commercialising therapeutics while building patient-centric organisations. He emphasises that "ultimate success is measured by the people you impact". Kevin most recently served as the Chief Commercial Officer of VectivBio, joining the company in November 2019 and continuing through its acquisition by Ironwood Pharmaceuticals in June 2023. As a pre-clinical biopharma company, we’re reminded of the importance of a comprehensive strategy that spans the entire lifecycle of a biotech product. Kevin’s insights into the critical stages of drug development underscore the significance of each phase in ensuring a successful product launch and commercialisation: Learn, Plan, Prepare, Go!   His experience in navigating regulatory approvals, scaling up manufacturing, and driving commercialisation have provided invaluable lessons for our team. We’re inspired to apply these insights as we advance our therapeutic candidates to make a meaningful impact on patients' lives.   #Biotech #Leadership #BioPharma #Healthcare #Innovation #PatientFirst